FDA-cleared profile

CardIQ Suite

GE Medical Systems SCS · CT/CTA · FDA-cleared (510(k))

Authorized purpose: CardIQ Suite analyzes 2D or 3D cardiac CT DICOM data for visualization and measurement of cardiovascular anatomy, coronary calcium scoring, coronary review, heart-fat estimation, and treatment or follow-up support under clinician review.

Clinical role
Post-processing and visualization for coronary review, calcium scoring, cardiovascular measurements, treatment planning, and follow-up; results remain subject to clinician interpretation.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: Calcium scoring is protocol-dependent and requires the stated gated non-contrast CT inputs. Heart-fat information is informational; all segmentation, measurements, and follow-up outputs require qualified clinical review. The regulatory results are not independent clinical-outcome evidence.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: CardIQ Suite analyzes 2D or 3D cardiac CT DICOM data for visualization and measurement of cardiovascular anatomy, coronary calcium scoring, coronary review, heart-fat estimation, and treatment or follow-up support under clinician review.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Cardiac CT DICOM data, including non-contrast and angiographic studies; calcium scoring requires ECG-gated non-contrast CT with 120 kVp, 24-35 cm DFOV, and slice thickness no greater than 3 mm.
  • Who uses it?Intended users: Qualified healthcare professionals reviewing cardiac CT; quantitative outputs are aids to clinical interpretation and decision-making.
  • What does the software produce?Output: Agatston and calcium-volume scores by vessel and total; coronary segmentation, labeling, centerline, and lumen measurements; heart and heart-fat segmentation/estimates; percentile context; DICOM Structured Report, batch DICOM Secondary Capture, and PDF report outputs.
  • What is its most important limitation?Key limitation: Calcium scoring is protocol-dependent and requires the stated gated non-contrast CT inputs. Heart-fat information is informational; all segmentation, measurements, and follow-up outputs require qualified clinical review. The regulatory results are not independent clinical-outcome evidence.

Clinical takeaway. Clinical role: CardIQ Suite analyzes 2D or 3D cardiac CT DICOM data for visualization and measurement of cardiovascular anatomy, coronary calcium scoring, coronary review, heart-fat estimation, and treatment or follow-up support under clinician review.

Evidence takeaway. Evidence from the reviewed source record: K243672 FDA evidence is a regulatory validation with heart-segmentation and heart-fat tests on 111 cardiac CT examinations and a separate lumen-diameter endpoint on 94 examinations containing 353 narrowings; overall totals and subgroup overlap were not reported, and no independent paper or trial was promoted in this timeboxed review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
CardIQ Suite analyzes 2D or 3D cardiac CT DICOM data for visualization and measurement of cardiovascular anatomy, coronary calcium scoring, coronary review, heart-fat estimation, and treatment or follow-up support under clinician review.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Post-processing and visualization for coronary review, calcium scoring, cardiovascular measurements, treatment planning, and follow-up; results remain subject to clinician interpretation.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Cardiac CT DICOM data, including non-contrast and angiographic studies; calcium scoring requires ECG-gated non-contrast CT with 120 kVp, 24-35 cm DFOV, and slice thickness no greater than 3 mm.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Agatston and calcium-volume scores by vessel and total; coronary segmentation, labeling, centerline, and lumen measurements; heart and heart-fat segmentation/estimates; percentile context; DICOM Structured Report, batch DICOM Secondary Capture, and PDF report outputs.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Cardiac CT, cardiology, radiology, and cardiovascular intervention planning or follow-up workflows.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Qualified healthcare professionals reviewing cardiac CT; quantitative outputs are aids to clinical interpretation and decision-making.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
Calcium scoring is protocol-dependent and requires the stated gated non-contrast CT inputs. Heart-fat information is informational; all segmentation, measurements, and follow-up outputs require qualified clinical review. The regulatory results are not independent clinical-outcome evidence.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
K243672 FDA evidence is a regulatory validation with heart-segmentation and heart-fat tests on 111 cardiac CT examinations and a separate lumen-diameter endpoint on 94 examinations containing 353 narrowings; overall totals and subgroup overlap were not reported, and no independent paper or trial was promoted in this timeboxed review.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K243672 FDA evidence is a regulatory validation with heart-segmentation and heart-fat tests on 111 cardiac CT examinations and a separate lumen-diameter endpoint on 94 examinations containing 353 narrowings; overall totals and subgroup overlap were not reported, and no independent paper or trial was promoted in this timeboxed review.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K243672 CardIQ Suite heart and heart-fat regulatory validation

  • DesignRetrospective regulatory validation of heart segmentation and heart-fat segmentation workflows.
  • Population111 cardiac CT examinations used for the FDA-described heart-segmentation and heart-fat tests.
  • Scopeexact submission
  • Tested versionCardIQ Suite configuration described in K243672
  • Samplen=111
  • IndependenceSponsor or vendor study

K243672

FDA reports heart-segmentation success greater than 90% and heart-fat average Dice of at least 90% in this test set; these are bounds, not observed numeric point estimates. The separate lumen-diameter endpoint used 94 examinations containing 353 narrowings; overall totals and subgroup overlap were not reported. Manufacturer-submitted regulatory evidence, not an independent clinical-outcome study.

K243672 CardIQ Suite lumen-diameter subgroup validation

  • DesignRetrospective regulatory validation of lumen-diameter measurements against reference measurements.
  • Population94 cardiac CT examinations containing 353 narrowings for the FDA-described lumen-diameter endpoint.
  • Scopeexact submission
  • Tested versionCardIQ Suite configuration described in K243672
  • Samplen=94
  • IndependenceSponsor or vendor study

K243672

This endpoint uses a subgroup distinct from the 111-examination heart and heart-fat validation context. No exact total unique-case count across the subgroups is inferred. Manufacturer-submitted regulatory evidence.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K243672. This does not establish absence of family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Cardiac CT DICOM data, including non-contrast and angiographic studies; calcium scoring requires ECG-gated non-contrast CT with 120 kVp, 24-35 cm DFOV, and slice thickness no greater than 3 mm.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K243672: CardIQ Suite

  2. Routing

    Source context, not route validation: The exact submission processes cardiac CT DICOM data and provides DICOM SR, batch SC, and PDF report outputs; local PACS/RIS routing, identifiers, and report ingestion require acceptance testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K243672: CardIQ Suite

  3. AI processing

    Source context, not route validation: The exact submission is deployed on the GE AW Server platform; reviewed sources do not establish the current site infrastructure, hosting topology, retention, availability, or service-level boundary for a particular installation.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K243672: CardIQ Suite

  4. Returned objects

    Source context, not route validation: Agatston and calcium-volume scores by vessel and total; coronary segmentation, labeling, centerline, and lumen measurements; heart and heart-fat segmentation/estimates; percentile context; DICOM Structured Report, batch DICOM Secondary Capture, and PDF report outputs.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K243672: CardIQ Suite

  5. Viewer/worklist/report

    Unresolved route: Agatston and calcium-volume scores by vessel and total; coronary segmentation, labeling, centerline, and lumen measurements; heart and heart-fat segmentation/estimates; percentile context; DICOM Structured Report, batch DICOM Secondary Capture, and PDF report outputs.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K243672: CardIQ Suite

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact submission is deployed on the GE AW Server platform; reviewed sources do not establish the current site infrastructure, hosting topology, retention, availability, or service-level boundary for a particular installation.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The exact submission processes cardiac CT DICOM data and provides DICOM SR, batch SC, and PDF report outputs; local PACS/RIS routing, identifiers, and report ingestion require acceptance testing.
  • Exact FDA submission
  • Checked 2026-09-07
Monitoring
Monitor protocol eligibility, calcium-score inputs, segmentation and measurement edits, report/export completeness, PACS delivery, reader overrides, failed or repeated analyses, downtime, updates, complaints, and recalls by exact K243672 release.
  • Exact FDA submission
  • Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and validation scope; it is not a claimed vendor monitoring service.

AW Server deployment

The exact FDA submission runs on the GE AW Server platform and processes cardiac CT DICOM studies; confirm the installed AW Server release, compute sizing, storage, backup, and upgrade path with the site and vendor.

exact submission · checked 2026-09-07

Integrated CardIQ workflow

GE describes CardIQ Suite as an integrated cardiac workflow for automated coronary territories, segmentation, scores, CCTA review, multiplanar views, and measurements; current page claims are family-level context for buyer workflow evaluation.

product family · checked 2026-09-07

Current GE family page; confirm which modules, licenses, and workflow features are included in the K243672 configuration.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243672
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-06-18
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No public list price or contract unit for the exact K243672 configuration was established in the reviewed official sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "GE HealthCare CardIQ Suite reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-07 - Exact FDA submission

    The reviewed exact packet, GE product page, and DICOM conformance statement do not establish current scoped security controls, certification scope, PHI flow, retention, access control, audit, or incident response.

  • Installation timeline: Not yet reviewed
  • Training: Not publicly available - checked 2026-09-07 - Exact FDA submission

    Reviewed sources establish qualified clinical use but do not establish an exact-version training curriculum, competency assessment, or support terms.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K243672: CardIQ Suite

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. CardIQ Suite model card (K243672)

    American College of Radiology - Published 2026-08-26 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. CardIQ Suite AW Advanced Visualization

    GE HealthCare - Accessed 2026-09-07

    Scope: productFamily, clinicalUse, implementationCapabilities, evidenceContext

  8. openFDA exact recall query for K243672

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

Research history

  1. K243672 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K251656

Careverse CoronaryDoc (Careverse CoronaryDoc)

Careverse Technology Pte. Ltd.

Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-09-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history